Trial Profile
Safety assessment of CIMAvax-EGF in patients with lung tumors of advanced non-small cell treated in Primary Health Care
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs BV NSCLC 001 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 01 Oct 2016 Results published in the Journal of Thoracic Oncology
- 29 Aug 2016 New trial record